Keywords: Forest Labs, Bystolic, Patent, Janssen, Johnson & Johnson, Watson Pharma, Teva, Lexapro, USA, FDA

Forest files suit over Bystolic patent; generic Lexapro launched in USA

Article | 15 March 2012

Print This

US drugmaker Forest Laboratories (NYSE: FRX) and Janssen Pharmaceutica, a unit of health care giant Johnson & Johnson (NYSE: JNJ), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in